Search results
Showing 4231 to 4245 of 8903 results
Subscribe to our GP reference panel and contribute to the development of NICE guidance in a quick and easy way.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
An approximate guide to the timings for the development of a piece of HealthTech guidance.
Our Medical Technologies Evaluation Programme (MTEP) considers technologies that could offer benefits to patients and the health and social care system over current practice.
Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.
We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.
Find out which guidance and quality standards are awaiting development
Home What NICE does Our guidance About HealthTech guidance NICE: backing the healthtech that changes lives {"@context":"http://schema.org","@ty
Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
With around 2 million healthtech products registered for UK use, differentiating your innovation from the competition is vital. A NICE recommendation helps you cut through the noise, demonstrate your product’s value and smooth your path to market.
Home News Articles {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/"
Home News...
Find out what guidance is being considered for development
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77